AUTHORS
Wenbin Yang, Wei Wang, PhD2, Hongyan Tong, MD, PhD3
AFFILIATIONS
1 Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China, Zhejiang Key Laboratory for Precision Diagnosis and Treatment of Hematological Malignancies, Hangzhou, China
2 Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China, Zhejiang Key Laboratory for Precision Diagnosis and Treatment of Hematological Malignancies, Hangzhou, China
3 Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China, Zhejiang Key Laboratory for Precision Diagnosis and Treatment of Hematological Malignancies, Hangzhou, China
ABSTRACT
Myelodysplastic neoplasms (MDS) with biallelic TP53 inactivation (MDS-biTP53) were recognized as a distinct subtype in the WHO 5th edition (2022) and is characterized by the presence of multiple TP53 mutations. Notably, multi-hit TP53 mutations in this disease identify a very-high-risk subtype, which is typically associated with complex cytogenetic abnormalities, rapid disease progression, and resistance to therapy. Thus, a detailed exploration of the molecular landscape of this subtype holds promise for uncovering actionable therapeutic targets.
In this study, we performed single-cell RNA sequencing (scFAST + Panel) on bone marrow mononuclear cells (BMMCs) from MDS-biTP53 patients (n = 4). BMMCs from TP53 wild-type MDS patients with different karyotypes (n = 17) and healthy donors (n = 4) were collected as disease and healthy controls, respectively. The scFAST platform was used for single-cell transcriptomic profiling, and targeted panel sequencing was employed to determine the mutational status of 407 hematological malignancy-related genes at the single-cell level.
We successfully identified aberrant cells harboring TP53 mutations. At the single-cell level, the fraction of TP53 mutation UMIs to total UMIs across covered sites was comparable to the variant allele frequency (VAF) determined by NGS, supporting the reliability of the scFAST + Panel approach. Cell-type composition analysis revealed that, compared with healthy donors, MDS patients exhibited an overall lymphoid-biased lineage composition. Although the MDS samples as a whole showed a lymphoid-biased cell-type composition, genotype-resolved analysis within the MDS-biTP53 samples revealed opposing lineage patterns between TP53 wild-type and TP53-mutant cells: the TP53 wild-type cells displayed a prominent lymphoid bias dominated by T cells and NK cells, with reduced proportions of myeloid cells and hematopoietic stem cells (HSCs); in contrast, the TP53-mutant cells exhibited a pronounced myeloid bias, characterized by a marked expansion of HSCs, MEPs, and erythroid cells, whereas lymphoid cells were extremely rare, consistent with previous reports.
Comprehensive GO and GSEA analyses of HSCs from the TP53 wild-type and TP53-mutant groups revealed fundamentally distinct transcriptional programs. HSCs in the TP53 wild-type group showed enrichment of RNA-processing and splicing pathways, whereas those in the TP53-mutant group exhibited marked upregulation of DNA damage repair and DNA replication pathways. Additionally, inflammatory response and cell differentiation pathways were relatively downregulated in the TP53-mutant group. Both the ranked gene list used for GSEA and the differentially expressed gene analysis highlighted members of the minichromosome maintenance family (MCMs). As core components of the DNA replication helicase complex, the upregulation of MCMs may reflect increased DNA replication activity and heightened replication stress in TP53-mutant HSCs. Notably, this upregulation of the MCMs tended to be independent of karyotypic abnormalities, suggesting a TP53 mutation-specific alteration.
We next validated this finding using multiplex immunohistochemistry (mIHC) on bone marrow samples from MDS patients. Compared with MDS patients without TP53 mutations, MDS-biTP53 patients exhibited aberrant accumulation of p53 protein and high expression of MCM4 and MCM6 proteins in bone marrow cells, accompanied by significant nuclear co-localization.
To investigate whether loss of p53 function increases cellular dependence on MCM proteins, we generated a TP53-knockout (TP53-KO) MOLM-13 cell line using CRISPR-Cas9 gene editing. Subsequently, MCMs were knocked down in both TP53-KO and TP53 wild-type MOLM-13 cells. The results showed that upon MCMs knockdown, TP53-KO cells exhibited significantly impaired proliferation, whereas TP53 wild-type cells were less affected. More importantly, knockdown of MCMs in the TP53-KO background significantly enhanced the sensitivity of MOLM-13 cells to chemotherapeutic agents, suggesting potential translational relevance for this strategy.
In summary, this study reveals that TP53 mutation increases reliance on DNA replication and repair programs in MDS HSCs. We further identified the MCMs as a potential therapeutic target in this subgroup, suggesting that targeting MCMs may represent a potential precision therapeutic strategy for TP53-mutant MDS. Further mechanistic and translational studies are in progress.
DISCLOSURES
Wenbin Yang: No relevant conflicts of interest to declare.